Spinal Cord Injury Neuroprotection With Glyburide

Part of paid clinical trials in Lexington, Kentucky.

Sponsor
Francis Farhadi
Study ID
NCT05426681
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Acute Spinal Cord Injury

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • GlyBURIDE Oral Tablet — DRUG
    Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of spinal cord injury. The dosing regimen involves an initial dose of 1.25mg followed by 11 consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2, and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively. Intervention: Drug: Glyburide

Study Details

To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.

Key Dates

Start date
Jul 7, 2022
Status verified
Feb 2026
Primary completion
May 31, 2027
Completion
May 31, 2028

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Glyburide treatment arm

Primary Outcome Measure

Rate of recruitment of patients with tSCI within the specified time window. [ Time Frame: within 8 hours of tSCI ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of KentuckyLexingtonKentucky40536
Francis Farhadi, MD, PhD
[email protected]
859-562-0247
Harshit Arora, PhD
[email protected]
859-323-4533

Find similar trials in Lexington, KY

By research site
University of Kentucky· Lexington, KY

Related Studies